Literature DB >> 11916913

Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response.

Salomon Banarer1, Veronica P McGregor, Philip E Cryer.   

Abstract

Because absence of the glucagon response to falling plasma glucose concentrations plays a key role in the pathogenesis of iatrogenic hypoglycemia in patients with insulin-deficient diabetes and the mechanism of this defect is unknown, and given evidence in experimental animals that a decrease in intraislet insulin is a signal to increased glucagon secretion, we examined the role of endogenous insulin in the physiological glucagon response to hypoglycemia. We tested the hypothesis that intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic-adrenomedullary, sympathetic neural, and parasympathetic neural-response and a low alpha-cell glucose concentration. Twelve healthy young adults were studied on three separate occasions. Insulin was infused in hourly steps in relatively low doses (1.5, 3.0, 4.5, and 6.0 pmol.kg(-1).min(-1)) from 60 through 300 min on all three occasions. Plasma glucose levels were clamped at euglycemia ( approximately 5.0 mmol/l, approximately 90 mg/dl) on one occasion and at hourly steps of approximately 4.7, 4.2, 3.6, and 3.0 mmol/l ( approximately 85, 75, 65, and 55 mg/dl) from 60 through 300 min on the other two occasions. On one of the latter occasions, the beta-cell secretagogue tolbutamide was infused in a dose of 1.0 g/h from 60 through 300 min. Hypoglycemia with tolbutamide infusion, compared with similar hypoglycemia alone, was associated with higher (P < 0.0001) C-peptide levels (final values of 1.0 +/- 0.2 vs. 0.1 +/- 0.0 nmol/l), higher (P < 0.0001) rates of insulin secretion (final values of 198 +/- 60 vs. 15 +/- 4 pmol/min), and higher (P < 0.0001) insulin levels (final values of 325 +/- 30 vs. 245 +/- 20 pmol/l) as expected. The glucagon response to hypoglycemia was prevented during tolbutamide infusion (P < 0.0001). Glucagon levels were 17 +/- 1 pmol/l at baseline on both occasions, 14 +/- 1 vs. 15 +/- 1 pmol/l, respectively, during the initial hyperinsulinemic euglycemia, and 15 +/- 1 vs. 22 +/- 2 pmol/l, respectively, during hypoglycemia with and without tolbutamide infusion. Autonomic-adrenomedullary (plasma epinephrine), sympathetic neural (plasma norepinephrine), and parasympathetic neural (plasma pancreatic polypeptide)-responses to hypoglycemia were not reduced during tolbutamide infusion. We conclude that intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response and a low alpha-cell glucose concentration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11916913     DOI: 10.2337/diabetes.51.4.958

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  57 in total

Review 1.  Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

Authors:  Philip E Cryer
Journal:  Endocrinology       Date:  2011-12-13       Impact factor: 4.736

Review 2.  Neuroendocrine responses to hypoglycemia.

Authors:  Nolawit Tesfaye; Elizabeth R Seaquist
Journal:  Ann N Y Acad Sci       Date:  2010-10-29       Impact factor: 5.691

3.  Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Authors:  F K Knop; T Vilsbøll; S Madsbad; J J Holst; T Krarup
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

Review 4.  Minireview: The role of the autonomic nervous system in mediating the glucagon response to hypoglycemia.

Authors:  Gerald J Taborsky; Thomas O Mundinger
Journal:  Endocrinology       Date:  2012-02-07       Impact factor: 4.736

5.  System-level control to optimize glucagon counterregulation by switch-off of α-cell suppressing signals in β-cell deficiency.

Authors:  Leon S Farhy; Anthony L McCall
Journal:  J Diabetes Sci Technol       Date:  2009-01

Review 6.  Paracrine signaling in islet function and survival.

Authors:  Sean M Hartig; Aaron R Cox
Journal:  J Mol Med (Berl)       Date:  2020-02-17       Impact factor: 4.599

7.  Counterregulatory responses to hypoglycemia differ between glimepiride and glyburide in non diabetic individuals.

Authors:  Nino G Joy; Donna B Tate; Stephen N Davis
Journal:  Metabolism       Date:  2015-02-26       Impact factor: 8.694

8.  Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo.

Authors:  Sachin A Paranjape; Owen Chan; Wanling Zhu; Adam M Horblitt; Ewan C McNay; James A Cresswell; Jonathan S Bogan; Rory J McCrimmon; Robert S Sherwin
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

9.  ATP-sensitive K+ channel mediates the zinc switch-off signal for glucagon response during glucose deprivation.

Authors:  Michela Slucca; Jamie S Harmon; Elizabeth A Oseid; Joseph Bryan; R Paul Robertson
Journal:  Diabetes       Date:  2009-10-06       Impact factor: 9.461

10.  Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans.

Authors:  Benjamin A Cooperberg; Philip E Cryer
Journal:  Diabetes Care       Date:  2009-09-03       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.